argenx SE | 6-K: argenx Announces Approval of VYVDURA Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.